21.5 C
New York
Wednesday, June 10, 2026

Tag: investors

newssourceFORcompanyinformationcontent1marketreleases

NBPE Announces Transaction in Own Shares

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Propurti Geeks Incorporated Celebrates Successful Launch of AI-Powered Property Management Platform at MacEwan University

Edmonton-born PropTech company draws property managers, investors, real estate operators, technology leaders, government representatives, academia, community leaders, and media to unveil the future of AI-assisted property operations 
Edmonton-born PropTech company draws property managers, investors, real estate operators, technology leaders, government representatives, academia, community leaders, and media to unveil the future of AI-assisted property operations

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.

MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn...

GeneDx (WGS) Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. 

VERI INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Veritone, Inc. Investors

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds Veritone, Inc. (“Veritone” or the “Company”) (NASDAQ:VERI) investors of the July 20, 2026 lead plaintiff deadline to seek lead plaintiff appointment in the class action filed on behalf of investors who acquired Veritone securities between October 14, 2025 through April 14, 2026 (“the Class Period”).

A&W ANNOUNCES MAJOR CANADIAN AIRPORT EXPANSION OF PRET A MANGER

New locations at major Canadian airports, including Vancouver International Airport, to begin opening this summer as Pret accelerates Canadian growthVANCOUVER, BC, June 9, 2026...

FUTU SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Futu Holdings Limited (“Futu” or the “Company”) (NASDAQ:FUTU) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

Robbins LLP Reminds CVLT Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action...

Robbins LLP is Investigating Allegations that Commvault Systems, Inc. (CVLT) Misled Investors Regarding its Annualized Recurring Revenue Growth

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Hut 8 Closes $4.25 Billion of Investment-Grade Senior Secured Notes for Beacon Point Data Center Project

Hut 8's second investment-grade data center construction bond — fully amortizing, non-recourse, and non-dilutive — rated Baa2 and priced 20 basis points inside the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInvestors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers